Astria Therapeutics to Present at Jefferies Healthcare Conference - May 30, 2024

Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company dedicated to creating transformative therapies for allergic and immunological conditions, has announced that Jill C. Milne, Ph.D., CEO, will engage in a fireside chat at the Jefferies Healthcare Conference. This event is scheduled for Thursday, June 6th, at 10:00 AM ET in New York, NY. 

Astria Therapeutics is committed to delivering groundbreaking treatments to individuals and families impacted by allergic and immunological diseases. The company is at the forefront of advancing its leading program, STAR-0215, which is a monoclonal antibody inhibitor targeting plasma kallikrein. This program is in clinical development for the management of hereditary angioedema, a rare and potentially life-threatening condition characterized by severe swelling. 

In addition to STAR-0215, Astria Therapeutics is also developing STAR-0310, a monoclonal antibody that acts as an OX40 antagonist. This program is currently in the preclinical phase and is aimed at treating atopic dermatitis, a chronic skin condition that causes inflammation and itching. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!